Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.90 0.33 +0.49%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC (RPRX) EPS (diluted)

Alert me on EPS (diluted)

Royalty Pharma PLC's EPS (diluted) for fiscal 2025 was $1.78, down 6.81% from $1.91 in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.40. Over the past ten years it has ranged from $0.10 (fiscal 2022) to $6.56 (fiscal 2019); the current reading is higher than 57% of that period. Royalty Pharma PLC ranks 33rd of 580 Biotechnology companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 $1.78 (6.81%)
FY2024 $1.91 (24.51%)
FY2023 $2.53 2,430.00%
FY2022 $0.10 (93.29%)
FY2021 $1.49 12.88%
FY2020 $1.32 (79.87%)
FY2019 $6.56 —

Quarterly newest first

Period EPS (diluted) Change
Sep 2026 $0.32 966.67%
Jun 2026 $0.03 (95.52%)
Mar 2026 $0.67 76.32%
Dec 2025 $0.38 (43.28%)
22 more quarters

Against its own ten years

Low $0.10 High $6.56
Ten-year median $1.78
Current reading's percentile 57

EPS (diluted) against peers

Company EPS (diluted)
ARGX argenex SE compare $28.66
ONC BeOne Medicines Ltd. - Sponsored ADR compare $5.68
INCY Incyte Corporation compare $1.88
RPRX Royalty Pharma PLC $1.40
GMAB Genmab A/S Sponsored ADR compare $1.27
ROIV Roivant Sciences Ltd. compare −$0.53
INSM Insmed, Inc. compare −$2.82
BNTX BioNTech SE Sponsored ADR compare −$6.85
RVMD Revolution Medicines, Inc. compare −$9.11

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on RPRX